United States Drug Patent 8,808,741: Scope, Claims, and Landscape Analysis
Patent US 8,808,741, titled "Pharmaceutical formulation comprising a COX-2 selective inhibitor and a proton pump inhibitor," was granted on November 11, 2014, to Merck Sharp & Dohme Corp. The patent covers pharmaceutical compositions containing celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, and a proton pump inhibitor (PPI) such as omeprazole. These formulations are designed to mitigate gastrointestinal adverse events associated with NSAID use.
What is the core innovation protected by US 8,808,741?
The primary innovation protected by US 8,808,741 is a fixed-dose combination pharmaceutical formulation that includes a COX-2 selective inhibitor and a proton pump inhibitor. Specifically, the patent claims compositions containing celecoxib, identified by its chemical name 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, and a proton pump inhibitor selected from a group including omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole, and mixtures thereof. The formulation is described as being suitable for oral administration.
What are the key claims of US 8,808,741?
The patent comprises multiple claims, with the independent claims defining the core subject matter.
-
Claim 1: A pharmaceutical composition comprising:
- (a) Celecoxib.
- (b) A proton pump inhibitor selected from the group consisting of omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole, and mixtures thereof.
The claim further specifies that the composition does not contain a buffering agent.
-
Claim 7: A pharmaceutical composition comprising:
- (a) Celecoxib.
- (b) Omeprazole.
The claim also specifies the absence of a buffering agent.
-
Claim 12: A method of treating or preventing gastrointestinal adverse events associated with the administration of a COX-2 selective inhibitor in a patient in need thereof, said method comprising administering to said patient a pharmaceutical composition comprising:
- (a) A COX-2 selective inhibitor.
- (b) A proton pump inhibitor selected from the group consisting of omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole, and mixtures thereof.
This claim explicitly excludes the administration of a buffering agent.
-
Claim 13: A method of treating or preventing gastrointestinal adverse events associated with the administration of celecoxib in a patient in need thereof, said method comprising administering to said patient a pharmaceutical composition comprising celecoxib and omeprazole. Similar to claim 12, this method also excludes the co-administration of a buffering agent.
The patent emphasizes specific embodiments, including those where the COX-2 selective inhibitor is celecoxib and the PPI is omeprazole, and crucially, the absence of a buffering agent in these formulations.
What is the patent's technical scope regarding formulation and administration?
The patent's technical scope focuses on oral pharmaceutical compositions. It defines the active pharmaceutical ingredients (APIs) as celecoxib and one or more specified PPIs. A significant aspect of the scope is the explicit exclusion of buffering agents. This exclusion suggests a deliberate design choice aimed at achieving specific pharmacokinetic profiles or stability for the combined APIs, or to differentiate from existing co-formulations that might employ buffering systems. The patent describes the composition in various forms, including tablets and capsules, intended for once-daily administration.
What is the patent's geographic and temporal coverage?
US 8,808,741 is a United States patent, granting exclusive rights within the U.S. territory. The patent was granted on November 11, 2014. The term of a U.S. patent is generally 20 years from the filing date, subject to maintenance fees. The filing date for this patent was July 29, 2013. Therefore, the patent is expected to expire on July 29, 2033, unless extended by patent term adjustments or other regulatory provisions.
What is the market context and prior art relevant to US 8,808,741?
The patent addresses a known therapeutic challenge: the gastrointestinal (GI) toxicity associated with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), particularly the increased risk of ulcers and bleeding with traditional NSAIDs. COX-2 selective inhibitors like celecoxib were developed to reduce these GI risks compared to non-selective NSAIDs, but they still carry a residual risk. Proton pump inhibitors (PPIs) are standard treatments for managing acid-related GI disorders and are frequently prescribed alongside NSAIDs to protect the stomach lining.
Prior art in this space includes numerous patents and publications detailing:
- Formulations of celecoxib for treating pain and inflammation.
- Various PPI formulations (e.g., delayed-release omeprazole, esomeprazole magnesium).
- Co-administration strategies for NSAIDs and PPIs, often involving separate pills taken concurrently or sequentially.
- Fixed-dose combination products for other drug classes.
A key prior art example is the combination product PREVACID® 24HR (lansoprazole delayed-release capsules), which treats frequent heartburn. Another relevant area is the development of delayed-release formulations of NSAIDs or co-formulations designed to improve GI tolerability. The innovation of US 8,808,741 lies in specifically claiming a fixed-dose combination formulation of celecoxib with a PPI, without a buffering agent, thereby offering a simplified dosing regimen for patients requiring both therapeutic effects.
What are potential challenges or points of contention for US 8,808,741?
Potential challenges to the validity or enforceability of US 8,808,741 primarily revolve around prior art and obviousness.
- Obviousness: Competitors may argue that combining a known COX-2 inhibitor (celecoxib) with a known gastroprotective agent (PPI) in a single formulation was obvious to a person skilled in the art, given the well-established GI risks of NSAIDs and the known benefits of PPIs. The absence of a buffering agent could be a point of contention, with arguments that its omission or inclusion would have been routine formulation development, or that its absence was not a critical inventive step.
- Anticipation: If prior art already disclosed a composition containing celecoxib and a PPI, even in a different form or with a buffering agent, it could potentially anticipate the claims.
- Enablement and Written Description: As with any patent, the specificity and clarity of the claims and their support within the patent specification are subject to scrutiny.
What is the current patent landscape for celecoxib and PPI combinations?
The patent landscape for celecoxib and PPI combinations is dynamic, with numerous patents related to celecoxib itself, PPIs, and various combination therapies. Patents covering celecoxib include its composition of matter (now expired) and various formulations and methods of use. Similarly, PPIs have a rich patent history.
For fixed-dose combinations specifically involving celecoxib and PPIs, US 8,808,741 represents one specific iteration. Other patents may cover different combinations of celecoxib with other PPIs, different formulation technologies (e.g., specific coating technologies, controlled-release mechanisms), or different therapeutic indications.
A notable example in the market is Duexis®, a fixed-dose combination product containing famotidine (an H2 blocker, not a PPI) and ibuprofen. While not directly overlapping in API composition, it demonstrates market interest in co-formulating analgesics with GI protectants. The direct combination of celecoxib and a PPI, as claimed in US 8,808,741, offers a distinct approach to GI protection in the context of COX-2 inhibition. Competitors seeking to enter this space would need to navigate around this patent, either by developing non-infringing formulations (e.g., using different APIs, different excipients if the absence of buffering is key, or different routes of administration) or by challenging the patent's validity.
Key Takeaways
US 8,808,741 protects a pharmaceutical formulation combining celecoxib with a specified list of proton pump inhibitors, notably excluding buffering agents. The patent aims to simplify the treatment regimen for patients requiring both pain relief and gastrointestinal protection. Its expiration date is July 29, 2033, after which generic versions of such fixed-dose combinations may become available, provided no other valid patents cover specific formulations or methods of use. The patent's enforceability hinges on its ability to withstand prior art and obviousness challenges, particularly concerning the novelty of the combination and the significance of the formulation's specific composition.
FAQs
-
What is the expiration date of US 8,808,741?
The patent is expected to expire on July 29, 2033.
-
Can a generic version of a celecoxib and PPI combination formulation be marketed before the patent expiration?
Market entry for generic versions of patented drugs prior to patent expiration typically requires a successful challenge to the patent's validity or a finding of non-infringement by the generic product.
-
Does US 8,808,741 cover the co-administration of celecoxib and a PPI as separate pills?
No, the patent specifically claims a pharmaceutical composition, indicating a single dosage form containing both active ingredients, not separate pills.
-
What is the significance of the "no buffering agent" limitation in the patent claims?
The exclusion of buffering agents is a specific technical limitation of the claimed formulations. Its exact significance may relate to drug stability, dissolution profiles, bioavailability, or differentiation from prior art.
-
Does US 8,808,741 cover all celecoxib and PPI combinations?
No, the patent covers specific combinations of celecoxib with a defined list of proton pump inhibitors and excludes buffering agents. Other combinations or formulations may fall outside the scope of this patent.
Citations
[1] Merck Sharp & Dohme Corp. (2014). Pharmaceutical formulation comprising a COX-2 selective inhibitor and a proton pump inhibitor (U.S. Patent No. 8,808,741). U.S. Patent and Trademark Office.
